Related Experiment Video

Updated: Jun 21, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer

Ates Kutay Tenekeci1, Ahmet Arda Unal1, Furkan Ceylan2

  • 1Hacettepe University School of Medicine, Ankara, Turkey.

Future Oncology (London, England)
|October 3, 2024
PubMed

Insights

KRAS G12C inhibitors like sotorasib and adagrasib represent a breakthrough in treating non-small cell lung cancer (NSCLC). These targeted therapies offer improved outcomes for patients with this specific KRAS mutation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • KRAS mutations, especially KRAS G12C, are key drivers in non-small cell lung cancer (NSCLC).
  • These mutations correlate with aggressive disease and resistance to standard treatments, necessitating targeted therapies.

Purpose of the Study:

  • To comprehensively review advancements in KRAS G12C inhibitors for NSCLC treatment.
  • To analyze pharmacokinetics, pharmacodynamics, adverse effects, biomarkers, and combination strategies for these inhibitors.

Main Methods:

  • Literature search of PubMed, Medline, ASCO, and ESMO abstracts up to June 5, 2024.
  • Keywords included "sotorasib", "adagrasib", "divarasib", and "KRAS G12C inhibitors".

Main Results:

  • KRAS G12C inhibitors, including sotorasib, adagrasib, and divarasib, have transformed NSCLC treatment.
  • Understanding drug properties and identifying predictive biomarkers are crucial for patient outcomes.

Conclusions:

  • KRAS G12C inhibitors offer a revolutionary approach to treating NSCLC patients with this mutation.
  • Ongoing research and clinical trials aim to further optimize survival and quality of life.
Keywords:
KRAS G12C inhibitorsadagrasibnon-small cell lung cancer (NSCLC)precision oncologyresistance mechanismssotorasibtargeted treatments

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...